直接口服抗凝剂(DOAC)水平超出预期范围患者的临床特征:一项回顾性图表研究

Q4 Medicine Thrombosis Update Pub Date : 2023-05-01 DOI:10.1016/j.tru.2023.100139
Dionne C.W. Braeken , Roisin Bavalia , Yvonne M.C. Henskens , Hugo ten Cate , Rutger C.C. Hengeveld , Barbara A. Hutten , Saskia Middeldorp , Michiel Coppens , An K. Stroobants
{"title":"直接口服抗凝剂(DOAC)水平超出预期范围患者的临床特征:一项回顾性图表研究","authors":"Dionne C.W. Braeken ,&nbsp;Roisin Bavalia ,&nbsp;Yvonne M.C. Henskens ,&nbsp;Hugo ten Cate ,&nbsp;Rutger C.C. Hengeveld ,&nbsp;Barbara A. Hutten ,&nbsp;Saskia Middeldorp ,&nbsp;Michiel Coppens ,&nbsp;An K. Stroobants","doi":"10.1016/j.tru.2023.100139","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Routine monitoring direct oral anticoagulants (DOAC) is not recommended, yet DOAC levels are frequently measured in clinical practice. Interpretation of levels, especially those outside expected ranges, is challenging. Until now it's unclear which patients are at risk for these levels.</p></div><div><h3>Aim</h3><p>Identify clinical characteristics of patients with DOAC levels outside expected ranges.</p></div><div><h3>Methods</h3><p>Patients of 2 Dutch academic medical centers with a DOAC concentration measured between 2012 and 2019 were included. DOAC levels above upper limit peak and below lower limit trough ranges, based on DOAC registration trials, were assigned outside expected range. Differences between patients were evaluated using Chi-square, independent sample-T tests and multivariable logistic regression analysis.</p></div><div><h3>Results</h3><p>Of 597 patients with DOAC measurement, 108 (18.1%) had levels outside expected ranges. Compared to patients with levels within range, patients with levels above range (n = 64) were older (71.1 vs. 60.6 years), more often had creatinine clearance &lt;50 ml/min (32.8% vs. 13.9%). and used more often interacting (17.2% vs. 6.7%) and/or antiplatelet co-medication (25.0% vs. 13.1%). Patients with levels above (62.5%) and below range (61.4%) more often had atrial fibrillation as DOAC indication versus patients with levels within range (39.1%). Age (OR 1.046 [1.025–1.068]) was associated with levels above range, while dabigatran versus apixaban was associated with levels below range (OR 6.060 [1.836–19.996]).</p></div><div><h3>Conclusion</h3><p>Particularly older aged patients with additional comorbidity and co-medication had DOAC levels outside expected ranges. Prospective studies are essential to investigate whether identification of patients with levels outside expected ranges is necessary to reduce the risk of clinically relevant adverse events.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study\",\"authors\":\"Dionne C.W. Braeken ,&nbsp;Roisin Bavalia ,&nbsp;Yvonne M.C. Henskens ,&nbsp;Hugo ten Cate ,&nbsp;Rutger C.C. Hengeveld ,&nbsp;Barbara A. Hutten ,&nbsp;Saskia Middeldorp ,&nbsp;Michiel Coppens ,&nbsp;An K. Stroobants\",\"doi\":\"10.1016/j.tru.2023.100139\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Routine monitoring direct oral anticoagulants (DOAC) is not recommended, yet DOAC levels are frequently measured in clinical practice. Interpretation of levels, especially those outside expected ranges, is challenging. Until now it's unclear which patients are at risk for these levels.</p></div><div><h3>Aim</h3><p>Identify clinical characteristics of patients with DOAC levels outside expected ranges.</p></div><div><h3>Methods</h3><p>Patients of 2 Dutch academic medical centers with a DOAC concentration measured between 2012 and 2019 were included. DOAC levels above upper limit peak and below lower limit trough ranges, based on DOAC registration trials, were assigned outside expected range. Differences between patients were evaluated using Chi-square, independent sample-T tests and multivariable logistic regression analysis.</p></div><div><h3>Results</h3><p>Of 597 patients with DOAC measurement, 108 (18.1%) had levels outside expected ranges. Compared to patients with levels within range, patients with levels above range (n = 64) were older (71.1 vs. 60.6 years), more often had creatinine clearance &lt;50 ml/min (32.8% vs. 13.9%). and used more often interacting (17.2% vs. 6.7%) and/or antiplatelet co-medication (25.0% vs. 13.1%). Patients with levels above (62.5%) and below range (61.4%) more often had atrial fibrillation as DOAC indication versus patients with levels within range (39.1%). Age (OR 1.046 [1.025–1.068]) was associated with levels above range, while dabigatran versus apixaban was associated with levels below range (OR 6.060 [1.836–19.996]).</p></div><div><h3>Conclusion</h3><p>Particularly older aged patients with additional comorbidity and co-medication had DOAC levels outside expected ranges. Prospective studies are essential to investigate whether identification of patients with levels outside expected ranges is necessary to reduce the risk of clinically relevant adverse events.</p></div>\",\"PeriodicalId\":34401,\"journal\":{\"name\":\"Thrombosis Update\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thrombosis Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266657272300010X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266657272300010X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

不建议常规监测直接口服抗凝剂(DOAC),但在临床实践中经常测量DOAC水平。解释水平,特别是那些超出预期范围的水平,是具有挑战性的。到目前为止,还不清楚哪些患者有这些水平的风险。目的探讨DOAC水平超出预期范围患者的临床特征。方法纳入2012 - 2019年间测量DOAC浓度的2个荷兰学术医疗中心的患者。DOAC水平高于上限峰值和低于下限波谷范围,基于DOAC注册试验,被分配到预期范围之外。采用卡方检验、独立样本t检验和多变量logistic回归分析评估患者之间的差异。结果597例DOAC检测患者中,108例(18.1%)的DOAC水平超出预期范围。与水平在范围内的患者相比,水平在范围以上的患者(n = 64)年龄较大(71.1岁对60.6岁),肌酐清除率≥50ml /min的患者较多(32.8%对13.9%)。并且更频繁地使用相互作用(17.2%对6.7%)和/或抗血小板联合用药(25.0%对13.1%)。与DOAC水平在该范围内(39.1%)的患者相比,DOAC水平高于(62.5%)和低于该范围(61.4%)的患者更常发生房颤。年龄(OR 1.046[1.025-1.068])与水平高于范围相关,而达比加群vs阿哌沙班与水平低于范围相关(OR 6.060[1.836-19.996])。结论:特别是有其他合并症和联合用药的老年患者DOAC水平超出预期范围。前瞻性研究对于调查是否有必要识别超出预期范围的患者水平以降低临床相关不良事件的风险至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study

Background

Routine monitoring direct oral anticoagulants (DOAC) is not recommended, yet DOAC levels are frequently measured in clinical practice. Interpretation of levels, especially those outside expected ranges, is challenging. Until now it's unclear which patients are at risk for these levels.

Aim

Identify clinical characteristics of patients with DOAC levels outside expected ranges.

Methods

Patients of 2 Dutch academic medical centers with a DOAC concentration measured between 2012 and 2019 were included. DOAC levels above upper limit peak and below lower limit trough ranges, based on DOAC registration trials, were assigned outside expected range. Differences between patients were evaluated using Chi-square, independent sample-T tests and multivariable logistic regression analysis.

Results

Of 597 patients with DOAC measurement, 108 (18.1%) had levels outside expected ranges. Compared to patients with levels within range, patients with levels above range (n = 64) were older (71.1 vs. 60.6 years), more often had creatinine clearance <50 ml/min (32.8% vs. 13.9%). and used more often interacting (17.2% vs. 6.7%) and/or antiplatelet co-medication (25.0% vs. 13.1%). Patients with levels above (62.5%) and below range (61.4%) more often had atrial fibrillation as DOAC indication versus patients with levels within range (39.1%). Age (OR 1.046 [1.025–1.068]) was associated with levels above range, while dabigatran versus apixaban was associated with levels below range (OR 6.060 [1.836–19.996]).

Conclusion

Particularly older aged patients with additional comorbidity and co-medication had DOAC levels outside expected ranges. Prospective studies are essential to investigate whether identification of patients with levels outside expected ranges is necessary to reduce the risk of clinically relevant adverse events.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Thrombosis Update
Thrombosis Update Medicine-Hematology
CiteScore
1.90
自引率
0.00%
发文量
33
审稿时长
86 days
期刊最新文献
Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO) Usability study of the qLabs® FIB: A new point-of-care system for functional fibrinogen testing Nitrous oxide and VTE – no laughing matter Practical model for implementation of cancer-associated thrombosis prevention in the outpatient setting
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1